Drug firm Strides Arcolab today said its subsidiary has received the American health regulator's approval to sell Vinorelbine injection, a cancer drug, in the American market.
Onco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab, has received final approval from US Food and Drug Administration (USFDA) for Vinorelbine Injection, Strides said in a statement.
"Vinorelbine is part of the oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch," it added.
Vinorelbine is used to treat various types of cancers. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.
Shares of Strides Arcolab were trading at Rs 819.50 on the BSE in late afternoon trade, down 1.21% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app